10 years of experience with thalidomide in multiple myeloma patients: Report of the Czech Myeloma Group
2013
Abstract
We analyzed 1156 multiple myeloma (MM) patients treated with thalidomide. The overall response rate was 63.6%, with complete remission in 13.4%.
Combined regimens had better outcomes than thalidomide plus dexamethasone or single agent thalidomide. Thalidomide was not able to overcome adverse cytogenetics.
Superior results were seen in patients undergoing subsequent autologous stem cell transplantation. The rate of adverse events was low.
Thalidomide has a strong potential to improve response and survival measures in patients with standard risk MM. Combined regimens should be used, with lower doses of thalidomide.
High risk myelomas should be treated individually.